News2025-03-14T18:43:32+00:00
News
Home»Company»News

News

Your source for the latest updates, breakthroughs, and insights in drug development and manufacturing. Explore our featured stories, press releases, and event announcements to stay informed about our innovations and contributions to drug development and manufacturing advancements.

1312, 2022

ASGCT Members Provide Recommendations During FDA Liaison Meeting

December 13th, 2022|Gene & Cell Therapy Testing|

ASGCT held its fifth annual liaison meeting with FDA CBER’s Office of Tissues and Advanced Therapies (OTAT) on Nov. 14, 2022. A group of Society leaders and members gave two presentations to FDA on significant topics in the field, followed by a presentation from FDA. Dr. Keith Wonnacott, ASGCT’s Regulatory Affairs Committee Chair, chaired the meeting and moderated discussion...

612, 2022

CG Oncology advancing clinical-stage urologic oncology immunotherapy pipeline

December 6th, 2022|Gene & Cell Therapy Testing, News|

Company files its first Investigational New Drug application for its lead program KYV-101, a novel fully human CD19 CAR T-cell therapy, for the treatment of lupus nephritis. Kyverna’s therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate...

911, 2022

CHOP Study Offers Proof of Concept for Treating Pediatric Brain Tumors with Immunotherapy

November 9th, 2022|Gene & Cell Therapy Testing, News|

Although immunotherapy has revolutionized the treatment of many blood cancers, the field has encountered challenges developing similar treatments for solid tumors. When it comes to pediatric brain tumors, which are the leading cause of cancer death in children, challenges include...

111, 2022

Remarkable results from CAR-T cell therapy for lupus

November 1st, 2022|Gene & Cell Therapy Testing, News|

A recent study has shown remarkable results from compassionate use of CAR-T cell therapy to treat severe lupus in five patients in whom multiple other treatments had previously failed. CAR-T cell therapy involves genetically engineering T cells, a type of immune cell, so that they respond to a prespecified molecular marker, or antigen. This means they mount an immune response against cells with the chosen antigen...

2610, 2022

Kyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis

October 26th, 2022|Gene & Cell Therapy Testing, News|

Company files its first Investigational New Drug application for its lead program KYV-101, a novel fully human CD19 CAR T-cell therapy, for the treatment of lupus nephritis. Kyverna’s therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate...

Go to Top